Your browser doesn't support javascript.
loading
Epidemiology, management, and burden of cytomegalovirus in solid organ transplant recipients in selected countries outside of Europe and North America: A systematic review.
Silva Junior, Helio Tedesco; Tokat, Yaman; Cai, Jinzhen; Singh, Inderjeet; Sandhu, Anudeep; Demuth, Dirk; Kim, Jongman.
Afiliação
  • Silva Junior HT; Division of Nephrology, Hospital do Rim, Federal University of Sao Paulo, Sao Paulo, Brazil.
  • Tokat Y; International Liver Center & Acibadem Healthcare Hospitals, Istanbul, Turkey.
  • Cai J; Organ Transplantation Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Singh I; Takeda Biopharmaceuticals India Pvt. Ltd, Gurugram, India.
  • Sandhu A; Takeda Pharmaceuticals International AG-Singapore Branch, Singapore, Singapore.
  • Demuth D; Takeda Pharmaceuticals International AG-Singapore Branch, Singapore, Singapore.
  • Kim J; Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Transpl Infect Dis ; 25(4): e14070, 2023 Aug.
Article em En | MEDLINE | ID: mdl-37254966
BACKGROUND: Cytomegalovirus (CMV) is a frequent infectious complication following solid organ transplantation (SOT). Considering significant differences in healthcare systems, a systematic review was conducted to describe the epidemiology, management, and burden of CMV post-SOT in selected countries outside of Europe and North America. METHODS: MEDLINE, Embase, and Cochrane databases were searched for observational studies in SOT recipients across 15 countries in the regions of Asia, Pacific, and Latin America (search period: January 1, 2011 to September 17, 2021). Outcomes included incidence of CMV infection/disease, recurrence, risk factors, CMV-related mortality, treatment patterns and guidelines, refractory and/or resistant CMV, patient-reported outcomes, and economic burden. RESULTS: Of 2708 studies identified, 49 were eligible (n = 43/49; 87.8% in adults; n = 34/49, 69.4% in kidney recipients). Across studies, selection of CMV preventive strategy was based on CMV serostatus. Overall, rates of CMV infection (within 1 year) and CMV disease post-SOT were respectively, 10.3%-63.2% (9 studies) and 0%-19.0% (17 studies). Recurrence occurred in 35.4%-41.0% cases (3 studies) and up to 5.3% recipients died of CMV-associated causes (11 studies). Conventional treatments for CMV infection/disease included ganciclovir (GCV) or valganciclovir. Up to 4.4% patients were resistant to treatment (3 studies); no studies reported on refractory CMV. Treatment-related adverse events with GCV included neutropenia (2%-29%), anemia (13%-48%), leukopenia (11%-37%), and thrombocytopenia (13%-24%). Data on economic burden were scarce. CONCLUSION: Outside of North America and Europe, rates of CMV infection/disease post-SOT are highly variable and CMV recurrence is frequent. CMV resistance and treatment-associated adverse events, including myelosuppression, highlight unmet needs with conventional therapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Órgãos / Infecções por Citomegalovirus / Leucopenia Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies / Systematic_reviews Aspecto: Patient_preference Limite: Adult / Humans País/Região como assunto: America do norte / Europa Idioma: En Revista: Transpl Infect Dis Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Órgãos / Infecções por Citomegalovirus / Leucopenia Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies / Systematic_reviews Aspecto: Patient_preference Limite: Adult / Humans País/Região como assunto: America do norte / Europa Idioma: En Revista: Transpl Infect Dis Ano de publicação: 2023 Tipo de documento: Article